ProCE Banner Activity

Phase III Trial of Pafolacianine Sodium Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer

Slideset Download
Conference Coverage
This phase III trial showed that pafolacianine sodium injection with intraoperative near-infrared fluorescence imaging detects additional lesions for surgical resection that would otherwise be missed by white light and palpation.

Released: June 09, 2021

Expiration: June 08, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme